SlideShare a Scribd company logo
Using patent information to track globalization ACS CHAL March 28th 2011 Yali Friedman, Ph.D. – info@thinkbiotech.com
Using patent information to track globalization Why it matters: Challenges of not having domestic drug R&D How to measure it: Using patents to track globalization of innovation
Global Biopharma Overview Location matters Workforce cost, availability Access to skilled management, supportive services Proximity to innovative science and markets Who is doing what, where?
Technology producers vs. consumers Global Biotechnology ,[object Object]
Gain foreign currency
Tax revenues from domestic companies and workersInnovators ,[object Object]
Non profit-enabling diseases are unlikely to attract investmentFollowers Importers Exporters
Strong market opportunities drive innovation Why is the U.S. the world leader in biotechnology? World’s largest prescription drug market Not divided like European countries World’s strongest patent protection World’s largest absolute expenditures on R&D The U.S. once spent more on R&D than the rest of the world combined No government price controls But, who is inventing the next generation of drugs?
What happens when you don’t develop drugs? Case Study: Philippines Limited domestic drug production capacity Must purchase essential medicines from foreign countries with higher wage-costs (e.g. Singapore) This is effectively reverse-offshoring Government has a limited budget, must make difficult decisions about how much of which vaccines to buy Domestic production would reduce costs, preserve foreign currency, keep revenues domestic, and could train workers for innovative drug development
Acquiring Medicines Develop a domestic drug development industry Pros: Can develop drugs for domestic needs, can drive tax revenues, can derive foreign currency from exports Cons: Expensive, takes time, requires unwavering government support Buy drugs from foreign countries: Pros: No need to invest in risky R&D, gain access to best drugs produced by global leaders Cons: Expensive, depletes foreign currency, doesn’t generate tax revenues Global Biotechnology
Solution: Produce foreign drugs locally Weak patent laws enable domestic production of drugs developed elsewhere Pros: Low-cost domestic production of many drugs using domestic workers, tax revenues from production and sales Cons: Reduced foreign investment by global firms, reduced motivation to develop drugs for locally-endemic conditions Global Biotechnology
Costs of Weak Patent Protection India (mostly) adopts TRIPS accords in 1995 Amends patent laws to protect product patents, with the notable extra criteria that new drug products must “differ significantly in properties with regard to efficacy” In 2007 Novartis failed to obtain a patent on Glivec (sold as Gleevec in the US) Novartis CEO: unfavorable patent ruling is “not an invitation to invest in Indian research and development.” Company will redirect hundreds of millions of dollars in investments to countries where it has greater IP protection. Global Biotechnology
Who benefits from not patenting Glivec? Novartis provides Glivec free to most patients in India Because Indian manufacturers would be unable to compete with Novartis’ free domestic distribution, their target markets would likely be in other countries, where they could potentially erode Novartis’ market. Is India forfeiting investments from Novartis simply so that Indian companies can sell Novartis’ drugs abroad? Does this serve the public? Global Biotechnology
Overcoming weak/poor markets Global Biotechnology Mectizan River blindness drug developed by Merck Affected individuals unable to pay for drug, so Merck distributes the drug for free This model is unsustainable. Doesn’t incentivize development of drugs for these conditions, instead relying on companies to support tangential discoveries. OneWorld Health, Bill & Melinda Gates Foundation, etc. Non-profit drug company solicits foundation support to actively develop shelved drugs for neglected populations
Meeting national needs: Economic Development Global Biotechnology Three basic models India, Brazil, Thailand Weak IP, focus on generic production and foreign sales Israel, Cuba, maybe India Moderate IP, leverage generic production skills to develop innovative drugs Singapore, Puerto Rico Strong IP, attract manufacturing investments from global leaders
Where are drugs invented? Friedman, Y. (2010) “Location of pharmaceutical innovation: 2000–2009” Nature Reviews Drug Discovery 9:835-836
Indexed patents covering FDA-approved drugs Source: DrugPatentWatch.com
Assigned relative inventorship based on inventor locations
US is slipping, EU stable, Asia rising

More Related Content

What's hot

Shivai Gupta - POSTER
Shivai Gupta - POSTERShivai Gupta - POSTER
Shivai Gupta - POSTER
Shivai Gupta
 
Investor presentation 20_december_2011
Investor presentation 20_december_2011Investor presentation 20_december_2011
Investor presentation 20_december_2011
rymankoly
 
Antares presentation -_january_2014
Antares presentation -_january_2014Antares presentation -_january_2014
Antares presentation -_january_2014
rymankoly
 
Generics, Industry on the Roll
Generics, Industry on the RollGenerics, Industry on the Roll
Generics, Industry on the Roll
rahulranjan138
 
Generic Medicine and its Future Prospects in India
 Generic Medicine and its Future Prospects in India Generic Medicine and its Future Prospects in India
Generic Medicine and its Future Prospects in India
Ankita Bharti
 
Originators and Princeps: How to face Biosimilars and Generics
Originators and Princeps: How to face Biosimilars and Generics      Originators and Princeps: How to face Biosimilars and Generics
Originators and Princeps: How to face Biosimilars and Generics
Joseph Pategou
 
applied strategic 10 years vision for biosimilars
applied strategic 10 years vision for biosimilarsapplied strategic 10 years vision for biosimilars
applied strategic 10 years vision for biosimilars
Richard Littlewood
 
Eli Lilly Global Strategy
Eli Lilly Global StrategyEli Lilly Global Strategy
Eli Lilly Global Strategy
guest90d5a
 
What is a biosimilar? All you need to know about the current biologics and bi...
What is a biosimilar? All you need to know about the current biologics and bi...What is a biosimilar? All you need to know about the current biologics and bi...
What is a biosimilar? All you need to know about the current biologics and bi...
Canadian Cancer Survivor Network
 
Biosimilars and Generics: A Comparison
Biosimilars and Generics: A Comparison      Biosimilars and Generics: A Comparison
Biosimilars and Generics: A Comparison
Joseph Pategou
 
Biosimilar Development EPTM 2015
Biosimilar Development EPTM 2015Biosimilar Development EPTM 2015
Biosimilar Development EPTM 2015
Ajaz Hussain
 
The new war on pharmaceutical drugs
The new war on pharmaceutical drugsThe new war on pharmaceutical drugs
The new war on pharmaceutical drugs
Duygu Can
 
Eli lilly and company
Eli lilly and companyEli lilly and company
Eli lilly and company
Chitkara University
 
Beyond the Business Plan - Managing unexpected risks in biotechnology busines...
Beyond the Business Plan - Managing unexpected risks in biotechnology busines...Beyond the Business Plan - Managing unexpected risks in biotechnology busines...
Beyond the Business Plan - Managing unexpected risks in biotechnology busines...
thinkBiotech
 
Global orphan drug market outlook 2018
Global orphan drug market outlook 2018Global orphan drug market outlook 2018
Global orphan drug market outlook 2018
Rajesh Sarma
 
Expanding Sandoz leadership in biosimilars
Expanding Sandoz leadership in biosimilarsExpanding Sandoz leadership in biosimilars
Expanding Sandoz leadership in biosimilars
Sandoz
 
Generic Drugs Michael Mc Namara May 12
Generic Drugs Michael Mc Namara May 12Generic Drugs Michael Mc Namara May 12
Generic Drugs Michael Mc Namara May 12
MichaelMcNamara
 
Us orphan drug market outlook 2018
Us orphan drug market outlook 2018Us orphan drug market outlook 2018
Us orphan drug market outlook 2018
Rajesh Sarma
 
Pharmaceutical Industry: The Challenges and the Opportunities
Pharmaceutical Industry: The Challenges and the OpportunitiesPharmaceutical Industry: The Challenges and the Opportunities
Pharmaceutical Industry: The Challenges and the Opportunities
European Industrial Pharmacists Group
 
Innovation and entrepreneurship in biotechnology an intl perspective - d. h...
Innovation and entrepreneurship in biotechnology   an intl perspective - d. h...Innovation and entrepreneurship in biotechnology   an intl perspective - d. h...
Innovation and entrepreneurship in biotechnology an intl perspective - d. h...
sanguru1977
 

What's hot (20)

Shivai Gupta - POSTER
Shivai Gupta - POSTERShivai Gupta - POSTER
Shivai Gupta - POSTER
 
Investor presentation 20_december_2011
Investor presentation 20_december_2011Investor presentation 20_december_2011
Investor presentation 20_december_2011
 
Antares presentation -_january_2014
Antares presentation -_january_2014Antares presentation -_january_2014
Antares presentation -_january_2014
 
Generics, Industry on the Roll
Generics, Industry on the RollGenerics, Industry on the Roll
Generics, Industry on the Roll
 
Generic Medicine and its Future Prospects in India
 Generic Medicine and its Future Prospects in India Generic Medicine and its Future Prospects in India
Generic Medicine and its Future Prospects in India
 
Originators and Princeps: How to face Biosimilars and Generics
Originators and Princeps: How to face Biosimilars and Generics      Originators and Princeps: How to face Biosimilars and Generics
Originators and Princeps: How to face Biosimilars and Generics
 
applied strategic 10 years vision for biosimilars
applied strategic 10 years vision for biosimilarsapplied strategic 10 years vision for biosimilars
applied strategic 10 years vision for biosimilars
 
Eli Lilly Global Strategy
Eli Lilly Global StrategyEli Lilly Global Strategy
Eli Lilly Global Strategy
 
What is a biosimilar? All you need to know about the current biologics and bi...
What is a biosimilar? All you need to know about the current biologics and bi...What is a biosimilar? All you need to know about the current biologics and bi...
What is a biosimilar? All you need to know about the current biologics and bi...
 
Biosimilars and Generics: A Comparison
Biosimilars and Generics: A Comparison      Biosimilars and Generics: A Comparison
Biosimilars and Generics: A Comparison
 
Biosimilar Development EPTM 2015
Biosimilar Development EPTM 2015Biosimilar Development EPTM 2015
Biosimilar Development EPTM 2015
 
The new war on pharmaceutical drugs
The new war on pharmaceutical drugsThe new war on pharmaceutical drugs
The new war on pharmaceutical drugs
 
Eli lilly and company
Eli lilly and companyEli lilly and company
Eli lilly and company
 
Beyond the Business Plan - Managing unexpected risks in biotechnology busines...
Beyond the Business Plan - Managing unexpected risks in biotechnology busines...Beyond the Business Plan - Managing unexpected risks in biotechnology busines...
Beyond the Business Plan - Managing unexpected risks in biotechnology busines...
 
Global orphan drug market outlook 2018
Global orphan drug market outlook 2018Global orphan drug market outlook 2018
Global orphan drug market outlook 2018
 
Expanding Sandoz leadership in biosimilars
Expanding Sandoz leadership in biosimilarsExpanding Sandoz leadership in biosimilars
Expanding Sandoz leadership in biosimilars
 
Generic Drugs Michael Mc Namara May 12
Generic Drugs Michael Mc Namara May 12Generic Drugs Michael Mc Namara May 12
Generic Drugs Michael Mc Namara May 12
 
Us orphan drug market outlook 2018
Us orphan drug market outlook 2018Us orphan drug market outlook 2018
Us orphan drug market outlook 2018
 
Pharmaceutical Industry: The Challenges and the Opportunities
Pharmaceutical Industry: The Challenges and the OpportunitiesPharmaceutical Industry: The Challenges and the Opportunities
Pharmaceutical Industry: The Challenges and the Opportunities
 
Innovation and entrepreneurship in biotechnology an intl perspective - d. h...
Innovation and entrepreneurship in biotechnology   an intl perspective - d. h...Innovation and entrepreneurship in biotechnology   an intl perspective - d. h...
Innovation and entrepreneurship in biotechnology an intl perspective - d. h...
 

Similar to Using patent information to track globalization

Indian pharma industry saurabh saxena
Indian pharma industry   saurabh saxenaIndian pharma industry   saurabh saxena
Indian pharma industry saurabh saxena
nparulekar
 
Final
FinalFinal
Indian pharmaceutical industry: Policies, achievements and challenges
Indian pharmaceutical industry: Policies, achievements and challengesIndian pharmaceutical industry: Policies, achievements and challenges
Indian pharmaceutical industry: Policies, achievements and challenges
Rajesh Kochhar
 
Pharmaceuticals and HIV/AIDS
Pharmaceuticals and HIV/AIDSPharmaceuticals and HIV/AIDS
Pharmaceuticals and HIV/AIDS
tchykita
 
Overview of the Pharma industry
Overview of the Pharma industryOverview of the Pharma industry
Overview of the Pharma industry
keyursavalia
 
Presentation
PresentationPresentation
Presentation
Dr Ashish Mankar
 
Health profits before people
Health profits before peopleHealth profits before people
Health profits before people
Suneeta Mohapatra
 
A review of marketing
A review of marketingA review of marketing
A review of marketing
Nilesh Shah
 
A review of marketing
A review of marketingA review of marketing
A review of marketing
Nilesh Shah
 
Implications for indian_pharmaceuticals
Implications for indian_pharmaceuticalsImplications for indian_pharmaceuticals
Implications for indian_pharmaceuticals
Akshay Bawa
 
Present Status and Scope of Pharmaceutical industry in India
Present Status and Scope of Pharmaceutical industry in IndiaPresent Status and Scope of Pharmaceutical industry in India
Present Status and Scope of Pharmaceutical industry in India
MadhuraNewrekar
 
new management trends in biopharmaceuticals
new management trends in biopharmaceuticalsnew management trends in biopharmaceuticals
new management trends in biopharmaceuticals
raj kunwar
 
Pharma
PharmaPharma
Pharma
nisha192
 
Are there reasons for believing that the profitability of the industry might ...
Are there reasons for believing that the profitability of the industry might ...Are there reasons for believing that the profitability of the industry might ...
Are there reasons for believing that the profitability of the industry might ...
Global Study Solutions - 9901366442
 
Chapter 2 pharmaceutical marketing by prof. n. s. lohe
Chapter 2 pharmaceutical marketing by prof. n. s. lohe Chapter 2 pharmaceutical marketing by prof. n. s. lohe
Chapter 2 pharmaceutical marketing by prof. n. s. lohe
Prof. Nikhil Lohe
 
Pharmaceutical Offshoring Landscape A Syndicated Report
Pharmaceutical Offshoring Landscape A Syndicated ReportPharmaceutical Offshoring Landscape A Syndicated Report
Pharmaceutical Offshoring Landscape A Syndicated Report
shekhar619
 
Pharmaceutical Industry Global & Indian
Pharmaceutical Industry Global & IndianPharmaceutical Industry Global & Indian
Pharmaceutical Industry Global & Indian
prateek_floyd
 
Drugs and pharmaceuticals
Drugs and pharmaceuticalsDrugs and pharmaceuticals
Drugs and pharmaceuticals
Thariq Asharaf
 
Newtech advant-business-plan9
Newtech advant-business-plan9Newtech advant-business-plan9
Newtech advant-business-plan9
Yousaf Khan
 
Indian Pharmaceutical Export Market - Top Export Destinations for Indian Phar...
Indian Pharmaceutical Export Market - Top Export Destinations for Indian Phar...Indian Pharmaceutical Export Market - Top Export Destinations for Indian Phar...
Indian Pharmaceutical Export Market - Top Export Destinations for Indian Phar...
Irish Pereira
 

Similar to Using patent information to track globalization (20)

Indian pharma industry saurabh saxena
Indian pharma industry   saurabh saxenaIndian pharma industry   saurabh saxena
Indian pharma industry saurabh saxena
 
Final
FinalFinal
Final
 
Indian pharmaceutical industry: Policies, achievements and challenges
Indian pharmaceutical industry: Policies, achievements and challengesIndian pharmaceutical industry: Policies, achievements and challenges
Indian pharmaceutical industry: Policies, achievements and challenges
 
Pharmaceuticals and HIV/AIDS
Pharmaceuticals and HIV/AIDSPharmaceuticals and HIV/AIDS
Pharmaceuticals and HIV/AIDS
 
Overview of the Pharma industry
Overview of the Pharma industryOverview of the Pharma industry
Overview of the Pharma industry
 
Presentation
PresentationPresentation
Presentation
 
Health profits before people
Health profits before peopleHealth profits before people
Health profits before people
 
A review of marketing
A review of marketingA review of marketing
A review of marketing
 
A review of marketing
A review of marketingA review of marketing
A review of marketing
 
Implications for indian_pharmaceuticals
Implications for indian_pharmaceuticalsImplications for indian_pharmaceuticals
Implications for indian_pharmaceuticals
 
Present Status and Scope of Pharmaceutical industry in India
Present Status and Scope of Pharmaceutical industry in IndiaPresent Status and Scope of Pharmaceutical industry in India
Present Status and Scope of Pharmaceutical industry in India
 
new management trends in biopharmaceuticals
new management trends in biopharmaceuticalsnew management trends in biopharmaceuticals
new management trends in biopharmaceuticals
 
Pharma
PharmaPharma
Pharma
 
Are there reasons for believing that the profitability of the industry might ...
Are there reasons for believing that the profitability of the industry might ...Are there reasons for believing that the profitability of the industry might ...
Are there reasons for believing that the profitability of the industry might ...
 
Chapter 2 pharmaceutical marketing by prof. n. s. lohe
Chapter 2 pharmaceutical marketing by prof. n. s. lohe Chapter 2 pharmaceutical marketing by prof. n. s. lohe
Chapter 2 pharmaceutical marketing by prof. n. s. lohe
 
Pharmaceutical Offshoring Landscape A Syndicated Report
Pharmaceutical Offshoring Landscape A Syndicated ReportPharmaceutical Offshoring Landscape A Syndicated Report
Pharmaceutical Offshoring Landscape A Syndicated Report
 
Pharmaceutical Industry Global & Indian
Pharmaceutical Industry Global & IndianPharmaceutical Industry Global & Indian
Pharmaceutical Industry Global & Indian
 
Drugs and pharmaceuticals
Drugs and pharmaceuticalsDrugs and pharmaceuticals
Drugs and pharmaceuticals
 
Newtech advant-business-plan9
Newtech advant-business-plan9Newtech advant-business-plan9
Newtech advant-business-plan9
 
Indian Pharmaceutical Export Market - Top Export Destinations for Indian Phar...
Indian Pharmaceutical Export Market - Top Export Destinations for Indian Phar...Indian Pharmaceutical Export Market - Top Export Destinations for Indian Phar...
Indian Pharmaceutical Export Market - Top Export Destinations for Indian Phar...
 

More from thinkBiotech

Defeating COVID-19
Defeating COVID-19Defeating COVID-19
Defeating COVID-19
thinkBiotech
 
Evaluating innovative portfolios and preparing for branded, 505(b)(2), and ge...
Evaluating innovative portfolios and preparing for branded, 505(b)(2), and ge...Evaluating innovative portfolios and preparing for branded, 505(b)(2), and ge...
Evaluating innovative portfolios and preparing for branded, 505(b)(2), and ge...
thinkBiotech
 
Finding and evaluating branded and generic market entry opportunities
Finding and evaluating branded and generic market entry opportunitiesFinding and evaluating branded and generic market entry opportunities
Finding and evaluating branded and generic market entry opportunities
thinkBiotech
 
When do drug patents expire and when can generic drugs launch?
When do drug patents expire and when can generic drugs launch?When do drug patents expire and when can generic drugs launch?
When do drug patents expire and when can generic drugs launch?
thinkBiotech
 
Educating the Next Generation of Biotechnology Managers and Founders
Educating the Next Generation of Biotechnology Managers and FoundersEducating the Next Generation of Biotechnology Managers and Founders
Educating the Next Generation of Biotechnology Managers and Founders
thinkBiotech
 
Innovating Across Borders
Innovating Across BordersInnovating Across Borders
Innovating Across Borders
thinkBiotech
 
Functional Overview of the Biotechnology Industry
Functional Overview of the Biotechnology IndustryFunctional Overview of the Biotechnology Industry
Functional Overview of the Biotechnology Industry
thinkBiotech
 

More from thinkBiotech (7)

Defeating COVID-19
Defeating COVID-19Defeating COVID-19
Defeating COVID-19
 
Evaluating innovative portfolios and preparing for branded, 505(b)(2), and ge...
Evaluating innovative portfolios and preparing for branded, 505(b)(2), and ge...Evaluating innovative portfolios and preparing for branded, 505(b)(2), and ge...
Evaluating innovative portfolios and preparing for branded, 505(b)(2), and ge...
 
Finding and evaluating branded and generic market entry opportunities
Finding and evaluating branded and generic market entry opportunitiesFinding and evaluating branded and generic market entry opportunities
Finding and evaluating branded and generic market entry opportunities
 
When do drug patents expire and when can generic drugs launch?
When do drug patents expire and when can generic drugs launch?When do drug patents expire and when can generic drugs launch?
When do drug patents expire and when can generic drugs launch?
 
Educating the Next Generation of Biotechnology Managers and Founders
Educating the Next Generation of Biotechnology Managers and FoundersEducating the Next Generation of Biotechnology Managers and Founders
Educating the Next Generation of Biotechnology Managers and Founders
 
Innovating Across Borders
Innovating Across BordersInnovating Across Borders
Innovating Across Borders
 
Functional Overview of the Biotechnology Industry
Functional Overview of the Biotechnology IndustryFunctional Overview of the Biotechnology Industry
Functional Overview of the Biotechnology Industry
 

Recently uploaded

Enhancing Adoption of AI in Agri-food: Introduction
Enhancing Adoption of AI in Agri-food: IntroductionEnhancing Adoption of AI in Agri-food: Introduction
Enhancing Adoption of AI in Agri-food: Introduction
Cor Verdouw
 
2024.06 CPMN Cambridge - Beyond Now-Next-Later.pdf
2024.06 CPMN Cambridge - Beyond Now-Next-Later.pdf2024.06 CPMN Cambridge - Beyond Now-Next-Later.pdf
2024.06 CPMN Cambridge - Beyond Now-Next-Later.pdf
Cambridge Product Management Network
 
Sustainable Logistics for Cost Reduction_ IPLTech Electric's Eco-Friendly Tra...
Sustainable Logistics for Cost Reduction_ IPLTech Electric's Eco-Friendly Tra...Sustainable Logistics for Cost Reduction_ IPLTech Electric's Eco-Friendly Tra...
Sustainable Logistics for Cost Reduction_ IPLTech Electric's Eco-Friendly Tra...
IPLTech Electric
 
GKohler - Retail Scavenger Hunt Presentation
GKohler - Retail Scavenger Hunt PresentationGKohler - Retail Scavenger Hunt Presentation
GKohler - Retail Scavenger Hunt Presentation
GraceKohler1
 
1 Circular 003_2023 ISO 27001_2022 Transition Arrangments v3.pdf
1 Circular 003_2023 ISO 27001_2022 Transition Arrangments v3.pdf1 Circular 003_2023 ISO 27001_2022 Transition Arrangments v3.pdf
1 Circular 003_2023 ISO 27001_2022 Transition Arrangments v3.pdf
ISONIKELtd
 
Satta Matka Dpboss Kalyan Matka Results Kalyan Chart
Satta Matka Dpboss Kalyan Matka Results Kalyan ChartSatta Matka Dpboss Kalyan Matka Results Kalyan Chart
Satta Matka Dpboss Kalyan Matka Results Kalyan Chart
Satta Matka Dpboss Kalyan Matka Results
 
欧洲杯赌球-欧洲杯赌球买球官方官网-欧洲杯赌球比赛投注官网|【​网址​🎉ac55.net🎉​】
欧洲杯赌球-欧洲杯赌球买球官方官网-欧洲杯赌球比赛投注官网|【​网址​🎉ac55.net🎉​】欧洲杯赌球-欧洲杯赌球买球官方官网-欧洲杯赌球比赛投注官网|【​网址​🎉ac55.net🎉​】
欧洲杯赌球-欧洲杯赌球买球官方官网-欧洲杯赌球比赛投注官网|【​网址​🎉ac55.net🎉​】
valvereliz227
 
The Steadfast and Reliable Bull: Taurus Zodiac Sign
The Steadfast and Reliable Bull: Taurus Zodiac SignThe Steadfast and Reliable Bull: Taurus Zodiac Sign
The Steadfast and Reliable Bull: Taurus Zodiac Sign
my Pandit
 
Satta Matka Dpboss Kalyan Matka Results Kalyan Chart
Satta Matka Dpboss Kalyan Matka Results Kalyan ChartSatta Matka Dpboss Kalyan Matka Results Kalyan Chart
Satta Matka Dpboss Kalyan Matka Results Kalyan Chart
Satta Matka Dpboss Kalyan Matka Results
 
一比一原版(QMUE毕业证书)英国爱丁堡玛格丽特女王大学毕业证文凭如何办理
一比一原版(QMUE毕业证书)英国爱丁堡玛格丽特女王大学毕业证文凭如何办理一比一原版(QMUE毕业证书)英国爱丁堡玛格丽特女王大学毕业证文凭如何办理
一比一原版(QMUE毕业证书)英国爱丁堡玛格丽特女王大学毕业证文凭如何办理
taqyea
 
Efficient PHP Development Solutions for Dynamic Web Applications
Efficient PHP Development Solutions for Dynamic Web ApplicationsEfficient PHP Development Solutions for Dynamic Web Applications
Efficient PHP Development Solutions for Dynamic Web Applications
Harwinder Singh
 
Satta Matka Dpboss Kalyan Matka Results Kalyan Chart
Satta Matka Dpboss Kalyan Matka Results Kalyan ChartSatta Matka Dpboss Kalyan Matka Results Kalyan Chart
Satta Matka Dpboss Kalyan Matka Results Kalyan Chart
Satta Matka Dpboss Kalyan Matka Results
 
Ellen Burstyn: From Detroit Dreamer to Hollywood Legend | CIO Women Magazine
Ellen Burstyn: From Detroit Dreamer to Hollywood Legend | CIO Women MagazineEllen Burstyn: From Detroit Dreamer to Hollywood Legend | CIO Women Magazine
Ellen Burstyn: From Detroit Dreamer to Hollywood Legend | CIO Women Magazine
CIOWomenMagazine
 
The Most Inspiring Entrepreneurs to Follow in 2024.pdf
The Most Inspiring Entrepreneurs to Follow in 2024.pdfThe Most Inspiring Entrepreneurs to Follow in 2024.pdf
The Most Inspiring Entrepreneurs to Follow in 2024.pdf
thesiliconleaders
 
1Q24_HYUNDAI CAPITAL SERVICES INC. AND SUBSIDIARIES
1Q24_HYUNDAI CAPITAL SERVICES INC. AND SUBSIDIARIES1Q24_HYUNDAI CAPITAL SERVICES INC. AND SUBSIDIARIES
1Q24_HYUNDAI CAPITAL SERVICES INC. AND SUBSIDIARIES
irhcs
 
8328958814KALYAN MATKA | MATKA RESULT | KALYAN
8328958814KALYAN MATKA | MATKA RESULT | KALYAN8328958814KALYAN MATKA | MATKA RESULT | KALYAN
8328958814KALYAN MATKA | MATKA RESULT | KALYAN
➑➌➋➑➒➎➑➑➊➍
 
Dpboss Matka Guessing Satta Matta Matka Kalyan panel Chart Indian Matka Dpbos...
Dpboss Matka Guessing Satta Matta Matka Kalyan panel Chart Indian Matka Dpbos...Dpboss Matka Guessing Satta Matta Matka Kalyan panel Chart Indian Matka Dpbos...
Dpboss Matka Guessing Satta Matta Matka Kalyan panel Chart Indian Matka Dpbos...
➒➌➎➏➑➐➋➑➐➐Dpboss Matka Guessing Satta Matka Kalyan Chart Indian Matka
 
The latest Heat Pump Manual from Newentide
The latest Heat Pump Manual from NewentideThe latest Heat Pump Manual from Newentide
The latest Heat Pump Manual from Newentide
JoeYangGreatMachiner
 
Cover Story - China's Investment Leader - Dr. Alyce SU
Cover Story - China's Investment Leader - Dr. Alyce SUCover Story - China's Investment Leader - Dr. Alyce SU
Cover Story - China's Investment Leader - Dr. Alyce SU
msthrill
 
Discover the Beauty and Functionality of The Expert Remodeling Service
Discover the Beauty and Functionality of The Expert Remodeling ServiceDiscover the Beauty and Functionality of The Expert Remodeling Service
Discover the Beauty and Functionality of The Expert Remodeling Service
obriengroupinc04
 

Recently uploaded (20)

Enhancing Adoption of AI in Agri-food: Introduction
Enhancing Adoption of AI in Agri-food: IntroductionEnhancing Adoption of AI in Agri-food: Introduction
Enhancing Adoption of AI in Agri-food: Introduction
 
2024.06 CPMN Cambridge - Beyond Now-Next-Later.pdf
2024.06 CPMN Cambridge - Beyond Now-Next-Later.pdf2024.06 CPMN Cambridge - Beyond Now-Next-Later.pdf
2024.06 CPMN Cambridge - Beyond Now-Next-Later.pdf
 
Sustainable Logistics for Cost Reduction_ IPLTech Electric's Eco-Friendly Tra...
Sustainable Logistics for Cost Reduction_ IPLTech Electric's Eco-Friendly Tra...Sustainable Logistics for Cost Reduction_ IPLTech Electric's Eco-Friendly Tra...
Sustainable Logistics for Cost Reduction_ IPLTech Electric's Eco-Friendly Tra...
 
GKohler - Retail Scavenger Hunt Presentation
GKohler - Retail Scavenger Hunt PresentationGKohler - Retail Scavenger Hunt Presentation
GKohler - Retail Scavenger Hunt Presentation
 
1 Circular 003_2023 ISO 27001_2022 Transition Arrangments v3.pdf
1 Circular 003_2023 ISO 27001_2022 Transition Arrangments v3.pdf1 Circular 003_2023 ISO 27001_2022 Transition Arrangments v3.pdf
1 Circular 003_2023 ISO 27001_2022 Transition Arrangments v3.pdf
 
Satta Matka Dpboss Kalyan Matka Results Kalyan Chart
Satta Matka Dpboss Kalyan Matka Results Kalyan ChartSatta Matka Dpboss Kalyan Matka Results Kalyan Chart
Satta Matka Dpboss Kalyan Matka Results Kalyan Chart
 
欧洲杯赌球-欧洲杯赌球买球官方官网-欧洲杯赌球比赛投注官网|【​网址​🎉ac55.net🎉​】
欧洲杯赌球-欧洲杯赌球买球官方官网-欧洲杯赌球比赛投注官网|【​网址​🎉ac55.net🎉​】欧洲杯赌球-欧洲杯赌球买球官方官网-欧洲杯赌球比赛投注官网|【​网址​🎉ac55.net🎉​】
欧洲杯赌球-欧洲杯赌球买球官方官网-欧洲杯赌球比赛投注官网|【​网址​🎉ac55.net🎉​】
 
The Steadfast and Reliable Bull: Taurus Zodiac Sign
The Steadfast and Reliable Bull: Taurus Zodiac SignThe Steadfast and Reliable Bull: Taurus Zodiac Sign
The Steadfast and Reliable Bull: Taurus Zodiac Sign
 
Satta Matka Dpboss Kalyan Matka Results Kalyan Chart
Satta Matka Dpboss Kalyan Matka Results Kalyan ChartSatta Matka Dpboss Kalyan Matka Results Kalyan Chart
Satta Matka Dpboss Kalyan Matka Results Kalyan Chart
 
一比一原版(QMUE毕业证书)英国爱丁堡玛格丽特女王大学毕业证文凭如何办理
一比一原版(QMUE毕业证书)英国爱丁堡玛格丽特女王大学毕业证文凭如何办理一比一原版(QMUE毕业证书)英国爱丁堡玛格丽特女王大学毕业证文凭如何办理
一比一原版(QMUE毕业证书)英国爱丁堡玛格丽特女王大学毕业证文凭如何办理
 
Efficient PHP Development Solutions for Dynamic Web Applications
Efficient PHP Development Solutions for Dynamic Web ApplicationsEfficient PHP Development Solutions for Dynamic Web Applications
Efficient PHP Development Solutions for Dynamic Web Applications
 
Satta Matka Dpboss Kalyan Matka Results Kalyan Chart
Satta Matka Dpboss Kalyan Matka Results Kalyan ChartSatta Matka Dpboss Kalyan Matka Results Kalyan Chart
Satta Matka Dpboss Kalyan Matka Results Kalyan Chart
 
Ellen Burstyn: From Detroit Dreamer to Hollywood Legend | CIO Women Magazine
Ellen Burstyn: From Detroit Dreamer to Hollywood Legend | CIO Women MagazineEllen Burstyn: From Detroit Dreamer to Hollywood Legend | CIO Women Magazine
Ellen Burstyn: From Detroit Dreamer to Hollywood Legend | CIO Women Magazine
 
The Most Inspiring Entrepreneurs to Follow in 2024.pdf
The Most Inspiring Entrepreneurs to Follow in 2024.pdfThe Most Inspiring Entrepreneurs to Follow in 2024.pdf
The Most Inspiring Entrepreneurs to Follow in 2024.pdf
 
1Q24_HYUNDAI CAPITAL SERVICES INC. AND SUBSIDIARIES
1Q24_HYUNDAI CAPITAL SERVICES INC. AND SUBSIDIARIES1Q24_HYUNDAI CAPITAL SERVICES INC. AND SUBSIDIARIES
1Q24_HYUNDAI CAPITAL SERVICES INC. AND SUBSIDIARIES
 
8328958814KALYAN MATKA | MATKA RESULT | KALYAN
8328958814KALYAN MATKA | MATKA RESULT | KALYAN8328958814KALYAN MATKA | MATKA RESULT | KALYAN
8328958814KALYAN MATKA | MATKA RESULT | KALYAN
 
Dpboss Matka Guessing Satta Matta Matka Kalyan panel Chart Indian Matka Dpbos...
Dpboss Matka Guessing Satta Matta Matka Kalyan panel Chart Indian Matka Dpbos...Dpboss Matka Guessing Satta Matta Matka Kalyan panel Chart Indian Matka Dpbos...
Dpboss Matka Guessing Satta Matta Matka Kalyan panel Chart Indian Matka Dpbos...
 
The latest Heat Pump Manual from Newentide
The latest Heat Pump Manual from NewentideThe latest Heat Pump Manual from Newentide
The latest Heat Pump Manual from Newentide
 
Cover Story - China's Investment Leader - Dr. Alyce SU
Cover Story - China's Investment Leader - Dr. Alyce SUCover Story - China's Investment Leader - Dr. Alyce SU
Cover Story - China's Investment Leader - Dr. Alyce SU
 
Discover the Beauty and Functionality of The Expert Remodeling Service
Discover the Beauty and Functionality of The Expert Remodeling ServiceDiscover the Beauty and Functionality of The Expert Remodeling Service
Discover the Beauty and Functionality of The Expert Remodeling Service
 

Using patent information to track globalization

  • 1. Using patent information to track globalization ACS CHAL March 28th 2011 Yali Friedman, Ph.D. – info@thinkbiotech.com
  • 2. Using patent information to track globalization Why it matters: Challenges of not having domestic drug R&D How to measure it: Using patents to track globalization of innovation
  • 3. Global Biopharma Overview Location matters Workforce cost, availability Access to skilled management, supportive services Proximity to innovative science and markets Who is doing what, where?
  • 4.
  • 6.
  • 7. Non profit-enabling diseases are unlikely to attract investmentFollowers Importers Exporters
  • 8. Strong market opportunities drive innovation Why is the U.S. the world leader in biotechnology? World’s largest prescription drug market Not divided like European countries World’s strongest patent protection World’s largest absolute expenditures on R&D The U.S. once spent more on R&D than the rest of the world combined No government price controls But, who is inventing the next generation of drugs?
  • 9. What happens when you don’t develop drugs? Case Study: Philippines Limited domestic drug production capacity Must purchase essential medicines from foreign countries with higher wage-costs (e.g. Singapore) This is effectively reverse-offshoring Government has a limited budget, must make difficult decisions about how much of which vaccines to buy Domestic production would reduce costs, preserve foreign currency, keep revenues domestic, and could train workers for innovative drug development
  • 10. Acquiring Medicines Develop a domestic drug development industry Pros: Can develop drugs for domestic needs, can drive tax revenues, can derive foreign currency from exports Cons: Expensive, takes time, requires unwavering government support Buy drugs from foreign countries: Pros: No need to invest in risky R&D, gain access to best drugs produced by global leaders Cons: Expensive, depletes foreign currency, doesn’t generate tax revenues Global Biotechnology
  • 11. Solution: Produce foreign drugs locally Weak patent laws enable domestic production of drugs developed elsewhere Pros: Low-cost domestic production of many drugs using domestic workers, tax revenues from production and sales Cons: Reduced foreign investment by global firms, reduced motivation to develop drugs for locally-endemic conditions Global Biotechnology
  • 12. Costs of Weak Patent Protection India (mostly) adopts TRIPS accords in 1995 Amends patent laws to protect product patents, with the notable extra criteria that new drug products must “differ significantly in properties with regard to efficacy” In 2007 Novartis failed to obtain a patent on Glivec (sold as Gleevec in the US) Novartis CEO: unfavorable patent ruling is “not an invitation to invest in Indian research and development.” Company will redirect hundreds of millions of dollars in investments to countries where it has greater IP protection. Global Biotechnology
  • 13. Who benefits from not patenting Glivec? Novartis provides Glivec free to most patients in India Because Indian manufacturers would be unable to compete with Novartis’ free domestic distribution, their target markets would likely be in other countries, where they could potentially erode Novartis’ market. Is India forfeiting investments from Novartis simply so that Indian companies can sell Novartis’ drugs abroad? Does this serve the public? Global Biotechnology
  • 14. Overcoming weak/poor markets Global Biotechnology Mectizan River blindness drug developed by Merck Affected individuals unable to pay for drug, so Merck distributes the drug for free This model is unsustainable. Doesn’t incentivize development of drugs for these conditions, instead relying on companies to support tangential discoveries. OneWorld Health, Bill & Melinda Gates Foundation, etc. Non-profit drug company solicits foundation support to actively develop shelved drugs for neglected populations
  • 15. Meeting national needs: Economic Development Global Biotechnology Three basic models India, Brazil, Thailand Weak IP, focus on generic production and foreign sales Israel, Cuba, maybe India Moderate IP, leverage generic production skills to develop innovative drugs Singapore, Puerto Rico Strong IP, attract manufacturing investments from global leaders
  • 16. Where are drugs invented? Friedman, Y. (2010) “Location of pharmaceutical innovation: 2000–2009” Nature Reviews Drug Discovery 9:835-836
  • 17. Indexed patents covering FDA-approved drugs Source: DrugPatentWatch.com
  • 18. Assigned relative inventorship based on inventor locations
  • 19. US is slipping, EU stable, Asia rising
  • 20. But, which are the leading countries?
  • 21. And… what about individual US states?
  • 22. Questions? Yali Friedman, Ph.D. info@thinkbiotech.com www.DrugPatentWatch.com www.CommercialBiotechnology.com